Related Experiment Video
Updated: Jan 2, 2026
08:21
Functional Assessment of the Donor Heart During Ex Situ Perfusion: Insights from Pressure-Volume Loops and Surface Echocardiography
Published on: October 11, 2022
2.5K
Refractory congestive heart failure: when the solution is outside the heart
Vicente Pernias1, Miguel González2, Gema Miñana1,3,4,5
1Fundación de Investigacion, Hospital Clínico Universitario de Valencia (INCLIVA), Valencia, Spain.
ESC Heart Failure
|December 14, 2019
Summary
Continuous ambulatory peritoneal dialysis (CAPD) offers a promising treatment for refractory congestive heart failure patients. This therapy improves quality of life and reduces hospital readmissions by enhancing sodium removal.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Refractory congestive heart failure (CHF) presents limited treatment options and a poor prognosis.
- Continuous ambulatory peritoneal dialysis (CAPD) is an emerging therapeutic alternative for select CHF patients.
- Effective management of fluid overload is critical in patients with cardiorenal syndrome.
Observation:
- A case study of an elderly patient with severe left ventricular dysfunction, mitral, and tricuspid regurgitation experiencing recurrent anasarca.
- The patient was enrolled in a continuous ambulatory peritoneal dialysis (CAPD) program.
- Despite persistent cardiac issues, the patient showed significant clinical and biochemical improvement post-CAPD initiation.
Findings:
- Continuous ambulatory peritoneal dialysis (CAPD) led to marked clinical improvement, including reduced edema.
- Biochemical markers improved, indicating better fluid and electrolyte balance.
- CAPD demonstrated superior sodium removal compared to conventional diuretic strategies.
Implications:
- Continuous ambulatory peritoneal dialysis (CAPD) is a valuable tool for managing volume excess in refractory heart failure with renal failure.
- This approach can improve quality of life and reduce hospitalizations in a challenging patient population.
- Further research into CAPD's role in cardiorenal syndrome is warranted.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
211
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
211
01:30Heart Failure V: Medical Management
176
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
176
01:22Heart Failure Drugs: Diuretics
751
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
751
01:30Cardiomyopathy II: Dilated Cardiomyopathy
400
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
400
01:30Heart Failure IV: Classification and Diagnostic Evaluation
259
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
259
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
849
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
849